Healthcare Industry News: HSMN NewsFeed
News Release - September 15, 2017
New eShunt System Presented at the American Academy of Neurological Surgery Annual meeting in Santa Barbara, CAEarly in vivo testing results show promise in treating communicating hydrocephalus
BOSTON, Sept. 15, 2017 -- (Healthcare Sales & Marketing Network) -- CereVasc, LLC, a company focused on improving the care of patients with communicating hydrocephalus announced today the presentation of early test data of its eShunt System at the annual meeting of the American Academy of Neurological Surgery. Carl Heilman, M.D., Professor and Chairman of the Department of Neurosurgery at Tufts Medical Center, Boston, MA, presented the results of bench-top, cadaver and animal testing that led to the development of the current eShunt System, to an audience of neurosurgical experts attending the annual scientific meeting.
"I think it was important to share our early results with the eShunt System with the well-informed audience that attends this meeting," said Dr. Heilman. "The need for new approaches for treatment of patients with this common neurological disorder is clear and meeting attendees with whom I spoke overwhelmingly expressed excitement and support for the eShunt approach."
"While its still early in the development of our technology, we believe that the eShunt System has the potential to transform the treatment of many patients who deal with the shortcomings of current, 60 year-old, open surgical standard of care," said Dan Levangie, Chairman of CereVasc, LLC. "The eShunt System represents an entirely new and novel approach that aligns very well with the recent migration of open neurosurgical procedures to minimally invasive, endovascular treatments."
About CereVasc, LLC
CereVasc, LLC is a medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. Their first product, the eShunt System is an endovascularly implantable cerebrospinal fluid (CSF) shunt and associated delivery componentry designed to avoid the need for invasive surgery, general anesthesia and hospitalization associated with the current surgical treatment of communicating hydrocephalus using ventriculo-peritoneal shunts. www.cerevasc.com
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.